Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ovary

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    507 result(s) found for: Ovary. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-001754-40 Sponsor Protocol Number: MITO - 7 Start Date*: 2009-02-18
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: WEEKLY vs EVERY 3 WEEK CARBOPLATIN + PACLITAXEL IN PATIENTS WITH OVARIAN CANCER: RANDOMIZED MULTICENTER STUDY
    Medical condition: PATIENTS WITH OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007107 Cancer of ovary LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005091-36 Sponsor Protocol Number: 2020-005091-36 Start Date*: 2021-08-30
    Sponsor Name:Stichting Catharina Hospital
    Full Title: Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070905 Ovarian cancer stage I PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    Population Age: Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016151-21 Sponsor Protocol Number: MITO - 11 Start Date*: 2010-08-04
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: A randomized multicentre phase II trial with pazopanib and weekly paclitaxel vs weekly paclitaxel in platinum resistant or refractory ovarian cancer
    Medical condition: platinum resistant or refractory ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033130 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000929-31 Sponsor Protocol Number: A/199/05 Start Date*: 2005-03-22
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Surgery plus intraperitoneal hyperthermic chemoterapy in platinum-resistant patients with ovarian cancer reccurrence. A Phase II study.
    Medical condition: Recurrent ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033128 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002540-26 Sponsor Protocol Number: A/644/05 Start Date*: 2006-02-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Evalutation of the effects of non pegylated liposomial doxorubicin MYOCET on the reduction of skin and cardiac toxicity in platinum resistant ovarian and endometrial cancer patients . A phase I...
    Medical condition: second line treatment in platinum resistant ovarian and endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033128 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000927-41 Sponsor Protocol Number: A/200/05 Start Date*: 2005-09-01
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Surgery plus intraperitoneal Hypertermic chemotherapy in platinum-sensitive patients with ovarian cancer recurrence after 12 months. Phase II study
    Medical condition: Recurrent ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033128 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001224-35 Sponsor Protocol Number: TaxOvar Start Date*: 2012-08-13
    Sponsor Name:Vejle Hospital
    Full Title: Cabazitaxel in platinum refractory ovarian cancer. A phase II trial
    Medical condition: Platinum refractory ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007925-38 Sponsor Protocol Number: HE 4/09 Start Date*: 2009-04-07
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: STUDY OF THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH CA125 ONLY RELAPSE OF OVARIAN CANCER A phase II study by the Hellenic Cooperative Oncology Group
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001373-16 Sponsor Protocol Number: CLIK066X2205 Start Date*: 2017-09-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject- and investigator-blinded, placebo-controlled pharmacodynamic study of oral LIK066 in overweight and obese women with polycystic ovary syndrome
    Medical condition: polycystic ovary syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10036050 Polycystic ovary LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003862-15 Sponsor Protocol Number: 2013-601 Start Date*: 2013-11-19
    Sponsor Name:Jens Faber
    Full Title: Liraglutide in Polycystic Ovary Syndrome A randomised, double-blind, placebo-controlled study of the effect of Liraglutide in Polycystic ovary syndrome on risk markers of vascular Thrombosis
    Medical condition: Polycystic Ovary Syndrome (PCOS), especialy signs of early cardiovascular disease in women with PCOS.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003962-40 Sponsor Protocol Number: S043VELC02 Start Date*: 2006-03-22
    Sponsor Name:FONDAZIONE SENDO
    Full Title: An open label, Phase II study of biweekly VELCADETM and intermittent CAELIXTM in patients with ovarian cancer failing platinum containing regimens
    Medical condition: ovarian cancer failing platinum containing regimens
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061535 Ovarian neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015927-94 Sponsor Protocol Number: PCOS NASH LIRAGLUTIDE Start Date*: 2010-02-08
    Sponsor Name:Hull and East Yorkshire NHS Trust
    Full Title: Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Liraglutide?
    Medical condition: Polycystic Ovary Syndrome Non-alcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065161 Polycystic ovarian syndrome LLT
    12.0 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006991-31 Sponsor Protocol Number: UOE/08/03 Start Date*: 2009-06-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Effect of the combined treatment with myo-inositol and metformin on the phenotype of the polycystic ovary syndrome: a pilot study
    Medical condition: polycystic ovary syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036049 Polycystic ovaries LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-001661-32 Sponsor Protocol Number: VeTo Start Date*: 2012-07-05
    Sponsor Name:Vejle Hospital, Dept. of Oncology
    Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status
    Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002571-25 Sponsor Protocol Number: 2017.corifollitropinalfa_IVM Start Date*: 2017-10-18
    Sponsor Name:UZ Brussel
    Full Title: A comparison between corifollitropin alfa and recombinant FSH for follicular recruitment in women with polycystic ovaries who undergo IVM treatment
    Medical condition: Infertile patients with polycystic ovaries
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000019245 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004506-34 Sponsor Protocol Number: 16.022 Start Date*: 2017-01-26
    Sponsor Name:Odense Universitetshospital
    Full Title: The effect of myoinositol (MI) or metformin treatment on symptoms of polycystisk ovary syndrome (PCOS), including metabolism, menstrual pattern, quality of life and mental health.
    Medical condition: Polycystic ovarian syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-004447-35 Sponsor Protocol Number: version 1, 05/08/2006 Start Date*: 2006-09-20
    Sponsor Name:Hull and East Yorkshire Hospital Trust
    Full Title: Biological Variation of Insulin Resistance, Testosterone and Cardiovascular Risk Factors In Women with Polycystic Ovarian Syndrome: modification with Rimonabant compared to Metformin.
    Medical condition: Patients with Polycystic Ovary Syndrome and body mass index above 30 kg/m2
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036049 Polycystic ovaries LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004531-38 Sponsor Protocol Number: ENDOPCOS02/2008 Start Date*: 2008-11-07
    Sponsor Name:Dr. Héctor Escobar Morreale
    Full Title: PROTOCOLO DE INVESTIGACIÓN SOBRE EL PERFIL DE RIESGO CARDIOVASCULAR ASOCIADO A MUJERES CON SÍNDROME DE OVARIO POLIQUÍSTICO O HIPERANDROGENISMO OVULATORIO, Y EVOLUCIÓN DEL MISMO DURANTE EL TRATAMIEN...
    Medical condition: Síndrome de ovario poliquístico
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036050 Polycystic ovary LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002091-15 Sponsor Protocol Number: NACARGPCOS Start Date*: 2005-11-23
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: POLICYSTIC OVARIAN SYNDROME AND NITRIC OXIDE. EFFECTS OF TREATMENT WITH N-ACETYLCYSTEINE AND ARGININE
    Medical condition: TO RESTORE A PHYSIOLOGICAL MESTRUAL CICLICITY AND OVULATION INCREASING THE PRODUCTION OF NITRIC OXIDE IN SUBJECTS WITH POLICYSTIC OVARIAN SYNDROME BY MEANS OF ARGININE AND ACETYLCYSTEINE ADMINISTRA...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036049 Polycystic ovaries LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006220-40 Sponsor Protocol Number: 2022-0101-01 Start Date*: 2022-06-30
    Sponsor Name:Hvidovre Hospital, Department of Gynecology
    Full Title: Double-blinded randomized placebo-controlled trial on tacrolimus in women with an euploid pregnancy loss and PCOS and/or thyroid autoimmunity
    Medical condition: Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    21.0 100000004848 10069094 Thyroid peroxidase antibody positive LLT
    20.1 100000004848 10060326 Thyroglobulin antibody positive LLT
    22.1 100000004868 10072314 Pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA